(Q40272437)

English

Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease

scientific article published on August 1, 1979

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 September 2017

Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease (English)

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

atherosclerosis

1 reference

based on heuristic

inferred from title

Cardiology and cardiovascular medicine

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

author name string

B. Vessby

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A228684

4 June 2022

H. Lithell

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A228684

4 June 2022

I. B. Gustafsson

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A228684

4 June 2022

J. Borberg

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A228684

4 June 2022

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=228684

4 June 2022

publication date

1 August 1979

1 reference

Europe PubMed Central

19 September 2017

full work available at URL

https://api.elsevier.com/content/article/PII:0021915079900388?httpAccept=text/xml

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

https://api.elsevier.com/content/article/PII:0021915079900388?httpAccept=text/plain

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Atherosclerosis

1 reference

Europe PubMed Central

19 September 2017

33

1 reference

Europe PubMed Central

19 September 2017

4

1 reference

Europe PubMed Central

19 September 2017

457-477

1 reference

Europe PubMed Central

19 September 2017

Hypercholesteremia with predisposition to atherosclerosis, an inborn error of lipid metabolism

1

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study

2

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study.

3

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Controlled trial of a diet high in unsaturated fat for prevention of atherosclerotic complications.

5

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes. A twelve-year clinical trial in men and women.

6

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Clofibrate in coronary heart disease. Effect on morbidity and mortality

7

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials

8

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

10

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Fat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders

11

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

12

0 references

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

13

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

14

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

A Methodological Study of an Intravenous Fat Tolerance Test with IntralipidREmulsion

18

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM

19

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

[On a rapid determination of the cholesterol bound to the serum alpha- and beta-lipoproteins]

20

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Quantitative and qualitative serum lipoprotein analysis. Part 1. Studies in healthy men and women

23

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

A general method for analysis of covariance structures

24

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Clinical and metabolic effects of pentaerythritol tetranicotinate in combination with cholesolvin or clofibrate.

25

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Dose-response effect of single and combined clofibrate (Atromidin®) and niceritrol (perycit®) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemia

26

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

27

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

29

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

30

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

31

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Serial lipid and lipoprotein responses to the American Heart Association fat-controlled diet

33

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

The Effect of Nicotinic Acid on the Plasma Free Fatty Acids Demonstration of a Metabolic Type of Sympathicolysis

35

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Drug treatment of hyperlipidemia

36

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

The effect of treatment with clofibrate on hepatic triglyceride and lipoprotein lipase activities of post heparin plasma in male patients with hyperlipoproteinemia

37

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia

38

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Comparison of assay methods for selective measurement of plasma lipase. The effect of clofibrate on hepatic and lipoprotein lipase in normals and patients with hypertriglyceridemia

39

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Increase of the lipoprotein-lipase activity in human skeletal muscle during clof ibrate administration

40

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Effects of clofibrate on fibrinolysis, platelet stickiness, plasma-fibrinogen, and serum-cholesterol

42

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Raised Erythrocyte Sedimentation Rate in Asymptomatic Hyperlipidaemia

43

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia.

45

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Regression and Progression of Early Femoral Atherosclerosis in Treated Hyperlipoproteinemic Patients

48

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid

49

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

4 June 2022

Effects of dietary treatment on lipoprotein levels in hyperlipoproteinaemia

16

1 reference

10.1016/0021-9150(79)90038-8

https://api.crossref.org/works/10.1016/0021-9150(79)90038-8

18 January 2023

Identifiers

10.1016/0021-9150(79)90038-8

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40272437&oldid=1814003878"